Recombinant Human Galectin-3 protein (His Tag)
ED50
3-12 ng/mL
Species
Human
Purity
>95 %, SDS-PAGE
GeneID
3958
Accession
P17931
验证数据展示
Technical Specifications
Purity | >95 %, SDS-PAGE |
Endotoxin Level | <1.0 EU/μg protein, LAL method |
Biological Activity |
Immobilized Human Galectin-3 (His tag) at 0.5 μg/mL (100 μL/well) can bind Human CD146 (GST tag) with a linear range of 3-12 ng/mL. |
Source | HEK293-derived Human Galectin-3 protein Ala2-Ile250 (Accession# P17931) with a His tag at the C-terminus. |
Predicted Molecular Mass | 26.8 kDa |
SDS-PAGE | 32-45 kDa, reducing (R) conditions |
Formulation | Lyophilized from sterile PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization. |
Reconstitution | Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water. |
Storage |
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
|
Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature. |
Background
Galectins are a family of animal lectins defined by shared characteristic amino-acid sequences and affinity for β-galactose-containing oligosac-charides. Galectin-3, a 31-kDa member of the β-galactoside-binding proteins, contains one carbohydrate recognition domain (CRD) and a proline- and glycine-rich N-terminal domain through which is able to form oligomers. Galectin-3 is widely expressed in many normal tissues and a variety of tumors. It is found intracellularly in nucleus and cytoplasm or secreted outside of cell, being present on the cell surface or in the extracellular space. Galectin-3 is involved in various biological processes including cell growth, adhesion, differentiation, apoptosis, angiogenesis, immune response, neoplastic transformation and metastasis. Elevated serum galectin-3 levels have been reported in patients with breast, gastrointestinal, lung, or ovarian cancer, melanoma, and non-Hodgkin's lymphoma.
References:
1. Barondes SH, et al. (1994) J Biol Chem. 269(33):20807-10. 2. Iurisci I, et al. (2000) Clin Cancer Res. 6(4):1389-93. 3. Takenaka Y, et al. (2002) Glycoconj J. 19(7-9):543-9. 4. Dumic J, et al.(2006) Biochim Biophys Acta. 1760(4):616-35.